“Biomarkers, Convergence Sciences and the Treatment Landscape of Advanced Prostate Cancer”
Manish Kohli, MD
Professor, Division of Oncology, School of Medicine
Jack R. and Hazel M. Robertson Presidential Endowed Chair
Huntsman Cancer Institute
University of Utah
Location: Clark, S360 & Zoom
Zoom Webinar Details
Webinar URL: https://stanford.zoom.us/s/96565890488
Dial US: +1 650 724 9799 or +1 833 302 1536
Webinar ID: 965 6589 0488
Passcode: 842288
ABSTRACT
The treatment landscape of metastatic prostate cancer has undergone a dynamic shift since 2015 onwards. Multiple drugs/drug combinations have emerged for treating metastatic hormone-sensitive and metastatic castrate-resistant states. This presentation will highlight the challenges of precision medicine delivery in the context of an ever-changing clinical standard of care in advanced prostate cancer. We will discuss our attempts of weaving biomarker development, health economic outcome analyses, bioengineering ultrasensitive detection technologies and augmented intelligence approaches into clinical practice for enhancing the delivery of precision healthcare in this clinical setting.
ABOUT
Dr. Manish Kohli started his career at the VA and University of Arkansas for Medical Sciences (UAMS) as an Assistant Professor. In 2005, he joined University of Rochester, New York as Associate Professor where he oversaw growth of genomic and liquid biopsy research. Subsequently Dr. Kohli joined Mayo Clinic, Rochester in 2008 to build a comprehensive Genitourinary Oncology translational and clinical research program. He was promoted to Consultant/Professor in 2016 and in 2019 appointed Vice-Chair of the Department of Genitourinary Oncology, a Distinguished Moffitt Scholar and Director of the DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center, Tampa. In 2020 he joined Huntsman Cancer Institute as a Presidential Endowed Chair in cancer research and Professor with tenure. His research focusses on advanced prostate cancer “convergence sciences” which combines population-based trials with precision medicine concepts. As part of this initiative, he works on multiple RO1s with colleagues at Stanford and University of Illinois for developing ultrasensitive liquid biopsy detection devices that profile molecular determinants of clinical outcomes.
Hosted by: Utkan Demirci, Ph.D.
Sponsored by: The Canary Center & the Department of Radiology
Stanford University – School of Medicine